Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: health insurance

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

Kimberly Retzlaff  |  September 8, 2016

The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsdrug updateinfliximabprescriptionpricingrheumatologistrheumatology

Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

Deborah Levenson  |  September 8, 2016

Be careful when prescribing allo­purinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have an increased…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:AllopurinolGoutoutcomepatient carerheumatologistriskskin reactionTreatmentUric acid

Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

Erin Blakemore  |  August 24, 2016

(Reuters Health)—Glucosamine sulfate and chondroitin sulfate are not more beneficial than placebo treatments for patients with knee osteoarthritis, a recent trial suggests. In a double-blind study, researchers investigated the efficacy of a medicine that delivered both glucosamine and chondroitin sulfate. The 164 participants all had osteoarthritis and moderate to severe knee pain. Half the participants…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & Rheumatologychondroitin sulfateglucosamine sulfatekneeKnee Osteoarthritis (OA)knee painplacebo

Prior Authorization Reform Achieves Some Success

Ryan Larosa, ACR staff  |  August 17, 2016

In early August, the American Medical Association (AMA) held its annual state advocacy strategy meeting in Chicago. This meeting pulls together all state medical societies and national specialty organizations. Over three days, participants engage in roundtable discussions on issues, solutions and best practices for health policy. Networking opportunities abound. The meetings showcase legislation that has…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:American Medical Association (AMA)electronic prior authorizationprior authorization

HIPAA Audit Activities Increase in 2016

Kelly Tyrrell  |  August 17, 2016

In the coming months, rheumatologists may want to pay particular attention to their email inboxes. By the end of the year, the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) will complete stage I, phase II of a series of desk and on-site audits designed to assess providers and their business…

Filed under:Practice SupportProfessional Topics Tagged with:HIPAA auditHIPAA complianceOffice for Civil Rights

HIPAA Cautions: The Problem with Personal Devices in Medical Practices

Richard Quinn  |  August 12, 2016

Should cell phones and other personal devices be used for work communications in a medical practice? According to one expert, these devices are a liability to rheumatologists and other providers, who should develop and enforce strict guidelines in their practices…

Filed under:Practice SupportTechnology Tagged with:HIPAAOffice of Civil RightspersonalPractice ManagementprivacyTechnology

The ACR and Partners Help Get Legislation Passed in New York to Limit Step Therapy

Mary Beth Nierengarten  |  August 4, 2016

In June, state lawmakers in New York passed legislation on step therapy designed to help ensure patient access to the best and most appropriate care. Step therapy mandates that a patient with a specific condition receive prescribed drugs approved for that condition in the order that an insurance company determines it will cover as the…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Legislation & Advocacystep therapy

U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers

Caroline Humer & Carl O'Donnell  |  July 22, 2016

NEW YORK (Reuters)—U.S. antitrust officials on Thursday moved to block an unprecedented consolidation of the national health insurance market, filing suit against Anthem Inc.’s proposed purchase of Cigna Corp. and Aetna Inc.’s planned acquisition of Humana Inc. The U.S. Department of Justice (DOJ) says the two mergers would reduce competition, raise prices for consumers and…

Filed under:Legal UpdatesLegislation & Advocacy Tagged with:Aetna Inc.Anthem Inc.Cigna Corp.Department of JusticeHealth InsuranceHumana Inc.Legalmerger

Practicing Telemedicine Raises Legal Considerations for Rheumatologists

Steven M. Harris, Esq.  |  July 12, 2016

With the evolution and advancement of technology, it was only a matter of time before such changes affected the medical industry. Although the concept of telemedicine dates back more than 50 years, emphasis on cost-effective quality healthcare coupled with technological advancements has caused a resurgence of telemedicine in recent years. What constitutes telemedicine largely depends…

Filed under:Legal UpdatesPractice Support Tagged with:DiagnosisLegalpatient carephysicianrheumatologistrheumatologyTechnologytelehealthtelemedicineTreatment

Avoid the Trap of Balance Billing

From the College  |  June 13, 2016

It is no secret that payers and providers have conflict as it relates to reimbursement rates for medical services, and there is another stakeholder, the patient, that plays an important role in the financial impact of healthcare reimbursement. Usually, patients are faced with unforeseen bills from their providers due to an unpaid portion of a…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:AC&RAmerican College of Rheumatology (ACR)CodingHealth InsuranceMedicaidMedicarePractice Managementrheumatologist

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 115
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences